Exact Mass: 494.3607
Exact Mass Matches: 494.3607
Found 370 metabolites which its exact mass value is equals to given mass value 494.3607
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Makisteron A
Makisterone A is a steroid. Makisterone A is a natural product found in Rhodnius prolixus, Dysdercus cingulatus, and other organisms with data available.
28-Homobrassinolide
28-Homobrassinolide is found in brassicas. 28-Homobrassinolide is a constituent of chinese cabbage (Brassica rapa ssp. pekinensis) Constituent of chinese cabbage (Brassica rapa sspecies pekinensis). 28-Homobrassinolide is found in brassicas.
1-docosanoyl-glycero-3-phosphate
1-docosanoyl-glycero-3-phosphate is classified as a member of the 1-acylglycerol-3-phosphates. 1-acylglycerol-3-phosphates are lysophosphatidic acids where the glycerol is esterified with a fatty acid at O-1 position. 1-docosanoyl-glycero-3-phosphate is considered to be practically insoluble (in water) and acidic. 1-docosanoyl-glycero-3-phosphate is a glycerophosphate lipid molecule
LysoPA(22:0/0:0)
LysoPA(22:0/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. LysoPA(22:0/0:0), in particular, consists of one chain of behenic acid at the C-1 position. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes.
LysoPA(i-22:0/0:0)
LysoPA(i-22:0/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. LysoPA(i-22:0/0:0), in particular, consists of one chain of isodocosanoic acid at the C-1 position. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes.
N-Nervonoyl Glutamine
N-nervonoyl glutamine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Glutamine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Glutamine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Glutamine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
DG(8:0/18:2(10E,12Z)+=O(9)/0:0)
DG(8:0/18:2(10E,12Z)+=O(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/18:2(10E,12Z)+=O(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/8:0/0:0)
DG(18:2(10E,12Z)+=O(9)/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(10E,12Z)+=O(9)/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/18:2(10E,12Z)+=O(9))
DG(8:0/0:0/18:2(10E,12Z)+=O(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/0:0/8:0)
DG(18:2(10E,12Z)+=O(9)/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(8:0/18:2(9Z,11E)+=O(13)/0:0)
DG(8:0/18:2(9Z,11E)+=O(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/18:2(9Z,11E)+=O(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/8:0/0:0)
DG(18:2(9Z,11E)+=O(13)/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(9Z,11E)+=O(13)/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/18:2(9Z,11E)+=O(13))
DG(8:0/0:0/18:2(9Z,11E)+=O(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/0:0/8:0)
DG(18:2(9Z,11E)+=O(13)/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(8:0/18:3(10,12,15)-OH(9)/0:0)
DG(8:0/18:3(10,12,15)-OH(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/18:3(10,12,15)-OH(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/8:0/0:0)
DG(18:3(10,12,15)-OH(9)/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(10,12,15)-OH(9)/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/18:3(10,12,15)-OH(9))
DG(8:0/0:0/18:3(10,12,15)-OH(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/0:0/8:0)
DG(18:3(10,12,15)-OH(9)/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(8:0/18:3(9,11,15)-OH(13)/0:0)
DG(8:0/18:3(9,11,15)-OH(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/18:3(9,11,15)-OH(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/8:0/0:0)
DG(18:3(9,11,15)-OH(13)/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(9,11,15)-OH(13)/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/18:3(9,11,15)-OH(13))
DG(8:0/0:0/18:3(9,11,15)-OH(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/0:0/8:0)
DG(18:3(9,11,15)-OH(13)/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
2-O-(2-methylbutyryl)-3-O-acetyl-alpha-bisabolol-beta-D-fucopyranoside|2-O-<2-methylbutyryl>-3-O-acetyl-alpha-bisabolol-beta-D-fucopyranoside
(E)-1-acetoxy-1,4-dihydro-2-methyl-4-oxo-3-phytylnaphthalene
2-hydroxymethyl-2,3,22,23-tetrahydroxy-6,10,15,19,23-pentamethyl-6,10,14,18-tetracosatetraene
8beta-hydroxy-15-malonyloxy-18-angeloyloxy-ent-labdane
5alpha-pregn-6-ene-3beta,17alpha,20(S)-triol-3-O-beta-D-digitalopyranoside|teikagenin-3-O-beta-D-digitaloside
8beta-hydroxy-15-malonyloxy-18-senecioyloxy-ent-labdane
3beta-acetoxyglutina-5(10),6-dien-27,8alpha-olide|phyllenolide A
(4aS)-1t,9t-di-furan-3-yl-4c,6a,12c,14a-tetramethyl-(4ar,6at,7ac,12ac,14at,15at)-hexadecahydro-[1,4]dioxino[2,3-c;5,6-c]diquinolizine|6beta,7beta-epoxy-deoxynupharidine dimer
1beta,3beta,14alpha,20beta,22beta,25-hexahydroxy-5beta-ecdysteroid|aervecdysteroid C
2,3,5,22,23-pentahydroxy-2,6,10,15,19,23-hexamethyl-6,10,14,18-tetracosatetraene
(1S, 8E,12E)-1-((2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-4,9,13,17-tetramethyl octadeca-8,12,16-triene-1,4,5-triol|sapelenin I
20(R)-25-methoxyl-dammarane-3beta,6alpha,12beta,20-tetrol
1-(3,7-dimethylocta-2,6-dienyl)-6,6,10,10-tetramethyl-11-(2-methylpropanoyl)tetracyclo[7.3.1.13,11.03,7]tetradecane-2,12,14-trione|hypersampsone C
ethyl (22S,25R)-3alpha,12alpha,15alpha,22-tetrahydroxy-5beta-cholestan-26-oate
(2-{6-[3-(2-dimethylamino-ethyl)-indol-2-yl]-7,7,9-trimethyl-6a,7,8,10a-tetrahydro-6H-isoindolo[2,1-a]indol-11-yl}-ethyl)-methyl-amine|4-Methyl-isoborreverin|Methyl-4-Isoborreverin
(8R,9S,22R)-3-ethoxy-3-oxo-9,19-cyclo-3,4-secolanosta-4(28),6,24-trien-26-oic acid 22,26-lactone
(2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,6-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
(2S,3R,10R,13R,14S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,5-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
(2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,6-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
(2S,3R,10R,13R,14S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,5-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one [IIN-based on: CCMSLIB00000847804]
(2S,3R,10R,13R,14S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,5-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one [IIN-based: Match]
His Ile Ile Ile
His Ile Ile Leu
His Ile Leu Ile
His Ile Leu Leu
His Leu Ile Ile
His Leu Ile Leu
His Leu Leu Ile
His Leu Leu Leu
Ile His Ile Ile
Ile His Ile Leu
Ile His Leu Ile
Ile His Leu Leu
Ile Ile His Ile
Ile Ile His Leu
Ile Ile Ile His
Ile Ile Leu His
Ile Leu His Ile
Ile Leu His Leu
Ile Leu Ile His
Ile Leu Leu His
Leu His Ile Ile
Leu His Ile Leu
Leu His Leu Ile
Leu His Leu Leu
Leu Ile His Ile
Leu Ile His Leu
Leu Ile Ile His
Leu Ile Leu His
Leu Leu His Ile
Leu Leu His Leu
Leu Leu Ile His
Leu Leu Leu His
(5Z,7E)-(1S,3R)-24,24-difluoro-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
(5Z,7E)-(1S,3R)-18-[m-(1-hydroxy-1-methylethyl)-benzyloxy]-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
Atocalcitol
Isohomobrassinolide
Cyathsterone D
Heptaethylene glycol monododecyl ether
D019999 - Pharmaceutical Solutions > D012597 - Sclerosing Solutions D013501 - Surface-Active Agents > D011092 - Polyethylene Glycols D013501 - Surface-Active Agents > D003902 - Detergents D001697 - Biomedical and Dental Materials D002317 - Cardiovascular Agents
benzyldimethyl[3-[(1-oxoisooctadecyl)amino]propyl]ammonium chloride
benzyldimethyl[3-[(1-oxooctadecyl)amino]propyl]ammonium chloride
Guanethidine sulfate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents
Homobrassinolide
28-Homobrassinolide is a phytosteroid. 28-Homobrassinolide can be used for the research of cholesterol and glucose homeostasis[1].
trimethyl-3-[(1-oxooctadecyl)amino]propylammonium methyl sulphate
[(2R)-1-hydroxy-3-phosphonooxypropan-2-yl] docosanoate
2-[[(2R)-3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(2S)-1-hydroxy-3-octanoyloxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-3-hydroxy-2-octanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2R)-2-hydroxy-3-octanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-2-hydroxy-3-octanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-1-hydroxy-3-octanoyloxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2S)-3-hydroxy-2-octanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2R)-2-hydroxy-3-octanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2S)-2-hydroxy-3-octanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
2-[[2-[(E)-hexadec-9-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[3-Carboxy-2-[13-(3,4-dimethyl-5-propylfuran-2-yl)tridecanoyloxy]propyl]-trimethylazanium
[3-carboxy-2-[(E)-7-[5-hydroxy-2-[(1E,5Z)-3-hydroxyocta-1,5-dienyl]-3-oxocyclopentyl]hept-5-enoyl]oxypropyl]-trimethylazanium
[3-Carboxy-2-[11-(3,4-dimethyl-5-pentylfuran-2-yl)undecanoyloxy]propyl]-trimethylazanium
2-[[3-[(E)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
Guanethidine bisulfate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents
3-(4-ethoxyphenyl)-1-[3-(4-morpholinyl)propyl]-1-[(1-propyl-3,4-dihydro-2H-quinolin-6-yl)methyl]urea
(2S,3R,10R,13R,14S)-2,3,14-Trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,5-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
O-[1-O-[(E)-9-Hexadecenoyl]-L-glycero-3-phospho]choline
2-[[(2R)-2-[(Z)-hexadec-9-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-[(Z)-heptadec-1-enoxy]-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[17-(5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
[3-Hydroxy-2-(nonanoylamino)decyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(propanoylamino)hexadecyl] 2-(trimethylazaniumyl)ethyl phosphate
(2-Acetamido-3-hydroxyheptadecyl) 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(octanoylamino)undecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Hexanoylamino)-3-hydroxytridecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Butanoylamino)-3-hydroxypentadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(pentanoylamino)tetradecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Heptanoylamino)-3-hydroxydodecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Decanoylamino)-3-hydroxynonyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(undecanoylamino)octyl] 2-(trimethylazaniumyl)ethyl phosphate
(1-hydroxy-3-octanoyloxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate
(1-hydroxy-3-nonanoyloxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate
(1-hydroxy-3-undecanoyloxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate
[1-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-tetradec-9-enoate
(1-decanoyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-heptadeca-9,12-dienoate
(1-heptanoyloxy-3-hydroxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate
(1-hydroxy-3-propanoyloxypropan-2-yl) (13Z,16Z)-tetracosa-13,16-dienoate
(1-hexanoyloxy-3-hydroxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate
(1-hydroxy-3-pentanoyloxypropan-2-yl) (13Z,16Z)-docosa-13,16-dienoate
2-[[3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
(3-hydroxy-2-undecanoyloxypropyl) (4E,7E)-hexadeca-4,7-dienoate
[1-carboxy-3-[2-hydroxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
2-[[2-[(Z)-hexadec-4-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-[(E)-hexadec-7-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(2S)-1-decanoyloxy-3-hydroxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate
[(2S)-2-decanoyloxy-3-hydroxypropyl] (9E,12E)-heptadeca-9,12-dienoate
[1-carboxy-3-[2-hydroxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
2-[[2-acetyloxy-3-[(Z)-tetradec-9-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-[(Z)-heptadec-9-enoxy]-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-propanoyloxy-3-[(Z)-tridec-9-enoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium
2,3,14-Trihydroxy-10,13-dimethyl-17-(2,3,6-trihydroxy-5,6-dimethylheptan-2-yl)-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
(3z,3as,5ar,7s,9ar,9bs)-3-[(3e,5e)-6,10-dimethyl-7-oxoundeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate
(1s,2r,4r)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6ah,7h,8h,10ah-benzo[c]isochromene-2-carboxylate
1-[5-(2h-1,3-benzodioxol-5-yl)-4-pentyl-6-(piperidine-1-carbonyl)cyclohex-2-ene-1-carbonyl]piperidine
1-isopropyl-4-methylcyclohex-3-en-1-yl 1-hydroxy-6,6,9-trimethyl-3-pentyl-6ah,7h,8h,10ah-benzo[c]isochromene-2-carboxylate
1-(2,3-dihydroxy-5,6-dimethylheptan-2-yl)-3a,7,8,10-tetrahydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one
(1s,3as,3br,5as,9as,9bs,11r,11as)-1-[(2s,3r,5r)-1-chloro-2,3-dihydroxy-5-[(1s,2r)-2-methylcyclopropyl]hexan-2-yl]-11-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one
(1r,2s,4s)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6ah,7h,8h,10ah-benzo[c]isochromene-2-carboxylate
[(2r,3r,4s,5r,6s)-6-{[(1s,4s,4ar,8as)-1,6-dimethyl-4-[(2r)-6-methylhept-5-en-2-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate
ethyl 3-[(1s,4r,5r,8s,9r,12s,13r)-4,8-dimethyl-5-[(1s)-1-[(2r)-5-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-12-(prop-1-en-2-yl)tetracyclo[7.5.0.0¹,¹³.0⁴,⁸]tetradec-10-en-13-yl]propanoate
(1r,4e,8e,12r,13r)-1-[(2s,5r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,9,13,17-tetramethyloctadeca-4,8,16-triene-1,12,13-triol
(1s,3as,5ar,7r,8s,9ar,9br,10r,11ar)-1-[(2r,3r)-2,3-dihydroxy-5,6-dimethylheptan-2-yl]-3a,7,8,10-tetrahydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one
6-{3,5,5a,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}-3-isopropylheptanoic acid
3-{[5-(2-hydroxy-2,5,8a-trimethyl-5-{[(3-methylbut-2-enoyl)oxy]methyl}-hexahydro-1h-naphthalen-1-yl)-3-methylpentyl]oxy}-3-oxopropanoic acid
ethyl 3-{4,8-dimethyl-5-[1-(5-methyl-6-oxo-2,3-dihydropyran-2-yl)ethyl]-12-(prop-1-en-2-yl)tetracyclo[7.5.0.0¹,¹³.0⁴,⁸]tetradec-10-en-13-yl}propanoate
3-(3,4-dihydroxy-5-methoxyphenyl)propyl 3-hydroxy-11-methyloctadecanoate
(2s,3r,4s,5s,6r)-4-(acetyloxy)-5-hydroxy-6-methyl-2-{[(2r)-6-methyl-2-[(1s)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-yl]oxy}oxan-3-yl (2r)-2-methylbutanoate
25- deoxysodium makisterone A
{"Ingredient_id": "HBIN004610","Ingredient_name": "25- deoxysodium makisterone A","Alias": "NA","Ingredient_formula": "C28H46O7","Ingredient_Smile": "CC(CC(C(C)(C1CCC2(C1(CCC3C2=CC(=O)C4C3(CC(C(C4)O)O)C)C)O)O)O)C(C)(C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "40221","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(2S,3R,4S,5S,6R)-2-[[(3S,8R,9S,10R,13S,14S,17R)-17-hydroxy-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-methoxy-6-methyloxane-3,5-diol
{"Ingredient_id": "HBIN006655","Ingredient_name": "(2S,3R,4S,5S,6R)-2-[[(3S,8R,9S,10R,13S,14S,17R)-17-hydroxy-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-methoxy-6-methyloxane-3,5-diol","Alias": "(2S,3R,4S,5S,6R)-2-[[(3S,8R,9S,10R,13S,14S,17R)-17-hydroxy-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-methoxy-6-methyl-tetrahydropyran-3,5-diol; (2S,3R,4S,5S,6R)-2-[[(3S,8R,9S,10R,13S,14S,17R)-17-hydroxy-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-methoxy-6-methyl-oxane-3,5-diol; (2S,3R,4S,5S,6R)-2-[[(3S,8R,9S,10R,13S,14S,17R)-17-hydroxy-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-methoxy-6-methyltetrahydropyran-3,5-diol","Ingredient_formula": "C28H46O7","Ingredient_Smile": "NA","Ingredient_weight": "494.66","OB_score": "21.59533771","CAS_id": "116709-66-1","SymMap_id": "SMIT07406","TCMID_id": "NA","TCMSP_id": "MOL005682","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}